alexa Chronic Lymphocytic Leukemia below the Radar | OMICS International
ISSN: 2329-6917
Journal of Leukemia
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Chronic Lymphocytic Leukemia below the Radar

Karl-Anton Kreuzer*

Department I of Internal Medicine, University at Cologne, Kerpener Strasse 62, 50937 Cologne – Germany

Corresponding Author:
Karl-Anton Kreuzer
Department I of Internal Medicine
University at Cologne, Kerpener Strasse 62
50937 Cologne – Germany
Tel: +49221478-97626
E-mail: [email protected]

Received Date: January 06, 2014; Accepted Date: January 14, 2014; Published Date: January 23, 2013

Citation: Kreuzer KA (2014 ) Chronic Lymphocytic Leukemia below the Radar J Leuk (Los Angel) 1:e104. doi: 10.4172/2329-6917.1000e104

Copyright: © 2014 Kreuzer KA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Leukemia

Chronic Lymphocytic Leukemia (CLL) has therefore recently stated that a new era is born for this entity. The first new compounds which will be shortly approved will be the anti-CD20 antibody obinutuzumab, the oral bruton tyrosine kinase inhibitor ibrutinib and the oral phosphoinositide-3-kinase inhibitor idelalisib[1]. However, a substantial number of additional agents with identical or different therapeutic targets are currently under clinical investigation and one cannot yet overview the numerous options which will be conceivable regarding any combination of those.


All these new approaches have in common that they frequently produce therapy responses which lie clearly below clinical or conventional hematological detection limits. Thus, to precisely assess the remaining disease burden more sensitive techniques such as multiparameter flow cytometry or molecular genetics have to be applied[2]. While flow cytometry is broadly available its detection limit is usually in the range of 1x104 . Real-time quantitative Polymerase Chain Reaction (qPCR) is more sensitive for detecting Minimal Residual Disease (MRD) below that level but is restricted to few highly specialised laboratories.

But do we really need this information? Isn’t CLL mostly a rather indolent disease which can be sufficiently be treated once it pops up again onto the radar after a period of low-level flying?

I think, these questions should be answered differentially depending on individual patient and disease characteristics. Certainly, MRD detection is of no established value in early disease stages where no treatment is indicated. So far no data exist showing that a given extend of monoclonal B lymphocytosis (MBL) or a defined amount of CLL cells predicts a progressive disease[3]. And the exact significance of established prognostic markers like molecular cytogenetics during early disease stages remains to be determined. Also, in most cases of manifest CLL with favourable prognostic factors (e.g. del(13q) or hypermutated immunoglobulin variable heavy chain, IgVH) disease monitoring by flow cytometry or molecular genetics is likely to be irrelevant. However, in the context with newer therapies it could be shown that remission depth has a significant impact on prognosis . Moreover, early detection of MRD may be of particular importance in high risk patients who underwent allogeneic stem cell transplantation [4].

Taken together, the new therapeutic era in CLL also challenges our diagnostic tools and requires their validation in an altered clinical setting.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12295
  • [From(publication date):
    March-2014 - Jul 17, 2018]
  • Breakdown by view type
  • HTML page views : 8488
  • PDF downloads : 3807

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7